The Russian technology leader in the production of modern medicines, Pharmasyntez, will release three types of recombinant human insulin (gensulins), namely, Gensulin M30, Gensulin N, and Gensulin R. The drug products will be produced at the Pharmasyntez-Nord site. The capacity of the plant for the production of insulin is more than 5 million units per year. Available dosage forms are vials, disposable insulin pens, and cartridges for reusable insulin pens.

Pharmasyntez also plans to launch the production of analog insulins, insulin glargine and insulin lispro, developed jointly with Gan & Lee Pharmaceuticals (China), this autumn. In this way, the Russian company will be able to comprehensively solve the important problem of providing Russian patients with high-quality Russian analogues of vital and essential drugs.

JSC Pharmasyntez-Nord (a part of the Pharmasyntez Group of Companies) is a modern pharmaceutical research and production complex specializing in the development and production of modern and effective drug products for the treatment of oncological and autoimmune diseases, as well as diseases of the endocrine system. At present, Pharmasyntez-Nord produces 45 trade names of oncological drugs, 99% of which are included in the list of vital and essential drugs of the Ministry of Health of the Russian Federation.

JSC Pharmasyntez-Nord operates in accordance with the requirements of Good Manufacturing Practice (GMP). The quality system functions at all stages of the drug product life cycle, from development to marketing, and is based on the principles of continuous improvement and a risk-based approach.